No registrations found.
ID
Source
Brief title
Health condition
Deep Venous Thrombosis, Pulmonary Embolism, D-dimer, Point-of-Care biomarker, primary care
Sponsors and support
Roche Diagnostics The Netherlands
De Friesland Insurance Company
Intervention
Outcome measures
Primary outcome
proximal DVT of the leg or Pulmonary Embolism
Secondary outcome
additional diagnostic information of (cardiac) biomarkers
Background summary
Venous thrombo-embolism (VTE), i.e. deep vein thrombosis (DVT) or pulmonary embolism (PE), poses a major diagnostic challenge for the general practitioner (GP) because signs and symptoms can be non-specific and even often quite minimal. The diagnostic work-up starts with scoring a clinical decision rule (CDR). If the CDR yields a low score (low VTE probability) a negative D-dimer test result can safely rule-out VTE without referral for imaging. However, the usability of this diagnostic approach is hampered in two clinical situations. First, D-dimer levels increase with increasing age (more false positives) and recently an age adjusted cut-off level for D-dimer test results was proposed to increase the diagnostic yield of D-dimer (i.e. better rule-out VTE) in elderly patients. Second, the most important differential diagnosis of VTE is an infectious disease (community-acquired pneumonia in the case of a primary suspicion of PE, or erysipelas in the case of a primary suspicion of DVT). In these cases, due to inflammation, D-dimer levels are also increased, in the absence of VTE, again decreasing the diagnostic yield of D-dimer.
The primary objective of this study is to perform a clinical and analytical validation of novel point-of-care (POC) D-dimer assays, in particular regarding their ability to rule-out VTE using an age-adjusted D-dimer cut-of. Secondary objectives are evaluating the added diagnostic information as obtained from inflammatory biomarkers (C-reactive protein and procalcitonin). Finally, we want to evaluate a novel biomarker for coagulation that has recently been developed (e.g. thrombin-anti-thrombin complex; TAT). We hypothesize that TAT-levels more accurately predict actual coagulation, and thus likely suffer less from false positive findings due to ageing or concurrent infectious diseases. For this purpose additional blood will be sampled and stored centrally in the “biobank” of the UMC Utrecht, allowing for future analyses for emerging novel biomarkers.
Study design
3 months
Intervention
None
R. Oudega
Universiteitsweg 100
Utrecht 3584 CG
The Netherlands
06-53152059
r.oudega@knmg.nl
R. Oudega
Universiteitsweg 100
Utrecht 3584 CG
The Netherlands
06-53152059
r.oudega@knmg.nl
Inclusion criteria
suspected DVT or PE with a low score on the Clinical Decision Rule
Exclusion criteria
age below 18, a high score on the CDR, ongoing anticoagulation, unable or unwilling to provide informed consent
Design
Recruitment
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
NTR-new | NL5974 |
NTR-old | NTR6348 |
CCMO | NL56475.041.16 |
OMON | NL-OMON46107 |